Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report

Area of Science:

• Oncology
• Hematology
• Immunomodulation

Background:

• Standard treatments for diffuse large B-cell lymphoma (DLBCL) include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with salvage cisplatin-based regimens and autologous stem cell transplant for relapsed cases.
• Treatment options for refractory DLBCL or those ineligible for stem cell transplant remain limited, often involving palliative care or clinical trials.
• Lenalidomide, an immunomodulatory drug with antiangiogenic properties, is being investigated for its efficacy in DLBCL.

Observation:

• A 55-year-old male with DLBCL experienced early relapse after R-CHOP and autologous stem cell transplant.
• Subsequent treatment with gemcitabine-cisplatin-rituximab provided only five months of efficacy before progression.
• The patient then received fourth-line therapy with lenalidomide, rituximab, and radiotherapy, followed by lenalidomide monotherapy.

Findings:

• The lenalidomide-based regimen significantly improved the patient's quality of life and performance status.
• This treatment resulted in over two years of progression-free survival, despite a brief relapse after treatment interruption.
• Lenalidomide demonstrated high effectiveness in this refractory DLBCL case.

Implications:

• Lenalidomide-based regimens represent a viable and effective therapeutic option for patients with refractory or relapsed diffuse large B-cell lymphoma.
• This case highlights the potential of lenalidomide in managing challenging DLBCL cases where standard therapies have failed.
• Further investigation into lenalidomide-containing regimens for DLBCL is warranted to establish its role in clinical practice.